Sequential chemotherapy with FEC(fluoraouracil, epirubicin and cyclophosphamide) and P+H(weekly Paclitaxel+Trastuzumab) as primary systemic therapy for operable breast cancer with HER2 positive disease-a phase 2 study
Phase 2
- Conditions
- Breast Cancer
- Registration Number
- JPRN-C000000265
- Lead Sponsor
- Breast Cancer PST Study Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 42
Inclusion Criteria
Not provided
Exclusion Criteria
severe complication suspicious of infection Hypersensitivity for polyoxyethylene castor oil (Cremophor EL) containing drugs grade 3 or 4 peripheral neuropathy Male breast cancer Pregnant or lactating women Doctor' s decision for exclusion
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method pathological complete rseponse rate
- Secondary Outcome Measures
Name Time Method clinical response, treatment compliance, breast-conserving rate, safety, overall survical, disease-free survival